The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over 'evergreening' practices in patent filings.
October 16, 2024 at 01:16AM
from Times of India
https://ift.tt/0giV9BD
Patent for HIV drug rejected, paves way for entry of generics
Subscribe to:
Post Comments (Atom)
It’s not just alcohol! 6 common habits are damaging your liver too
Many daily habits silently harm the liver. Excessive sugar intake causes fatty liver. Overusing painkillers strains liver function. Sedentar...
-
Several notable WWE veterans passed away in 2024, including Sika Anoa'i, Francisco Ciatso, Akebono, Ole Anderson, and Virgil. These wres...
-
Supreme Court on Tuesday rejected pleas for a retest for admissions to 1.08 lakh MBBS seats in govt and private medical colleges in the abse...
-
Horoscope Today: Read daily horoscope predictions for December 7, 2024. Know all about the astrological events and influences that will be a...
No comments:
Post a Comment